HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US HHS Pulled Recommendation To Make Kratom A Controlled Substance, But Kept Mum On Change

Agency Recently Disclosed 2018 Letter To DEA Rescinding Findings To Schedule Kratom

Executive Summary

HHS released to industry proponents Reps. Mark Pocan and Morgan Griffith the letter it submitted in 2018 notifying DEA that it was rescinding recommendation it made in 2017 to list kratom active ingredients mitragynine and 7-hydroxymitragynine under Schedule I of the CSA.

You may also be interested in...

US Kratom Industry Chafes At FDA’s Short Leash On Science Showing Botanical’s Safety, Benefits

American Kratom Association didn’t convince court to order FDA to extend to deadline for comments responding to World Health Organization’s question on whether kratom should be deemed controlled substances under UN schedule. Short comment period is “latest in what we think is a very hostile action” by FDA about kratom, says AKA executive Mac Haddow.

FDA’s Proposed IND Study For ‘Abuse Potential’ Could Close US Kratom Supplement Market

RFP states FDA "previously warned consumers about the use of Kratom (Mitragyna speciosa)” and although botanical’s “use is prevalent, to date, clinical evaluations of abuse potential have not been performed.”

Another Notice For Comments On Kratom: Cue Second Wave Of Support For Botanical In US?

FDA states in Federal Register notice that WHO has requested information on whether kratom – mitragynine, 7-hydroxymitragynine – should be added to the United Nations’ schedule of controlled substances.

Related Content


Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts